Axsome Therapeutics (NASDAQ:AXSM) announced that the U.S. Food and Drug Administration has approved Auvelity for the ...

Alzheimer’s disease agitation could mean peak sales of over $2.1 billion for Axsome’s Auvelity, according to analysts at ...

The FDA has approved Auvelity for treating agitation in patients with dementia due to Alzheimer’s disease, Axsome ...

Axsome Therapeutics has received the US Food and Drug Administration (FDA) approval for Auvelity (dextromethorphan HBr and ...

By Kamal Choudhury and Mariam Sunny April 30 (Reuters) - The U.S. Food and Drug Administration has approved Axsome ...

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...

Should you receive a diagnosis of AD, many factors shape how symptoms unfold. The brain, even when under siege, retains an ...

Axsome Therapeutics (AXSM) stock is in focus as the FDA OKs a label expansion for the firm's depression drug Auvelity in ...

Subtle biological changes linked to Alzheimer's disease may begin as early as the late 50s—decades before memory loss or ...

New research identifies critical ages for Alzheimer's biomarkers, enhancing screening strategies and understanding ...

Researchers at the Indiana University School of Medicine have developed a new way to read the brain's "energy network ...

Researchers at UC San Diego say they recently uncovered new insights into a protein that has emerged as a potential molecular “switch” that may determine whether Alzheimer’s-like brain changes lead to ...